ChemicalBook
Chinese english Germany Korea

セフタジジム

セフタジジム 化学構造式
78439-06-2
CAS番号.
78439-06-2
化学名:
セフタジジム
别名:
セフタジジム五水和物(CONTAIN 1 EQUIVALENT OF NA2CO3 AS STABILIZER);セフタジジム五水和物;セフタジジム;セフタジジム水和物;セフタジジム水和物 (JP17)
英語化学名:
Ceftazidime
英語别名:
Kefazim;CEFTAZIME;Ceftazidime;Ceftazidime;cazpentahydrate;sn401pentahydrate;gr20263pentahydrate;CEFTAZIDIME PENTAHYDRATE;Ceftazidieme Pentahydrate;Ceftazidime Pentahydrate, >=99%
CBNumber:
CB3246290
化学式:
C22H32N6O12S2
分子量:
636.65
MOL File:
78439-06-2.mol

セフタジジム 物理性質

融点 :
>1500C (dec.)
RTECS 番号:
UU2230000
貯蔵温度 :
2-8°C
溶解性:
Sparingly soluble in aqueous solution
酸解離定数(Pka):
pKa 1.8 (Uncertain)
外見 :
neat
CAS データベース:
78439-06-2(CAS DataBase Reference)
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
主な危険性  Xn
Rフレーズ  42/43
Sフレーズ  22-36/37-45-37-24
WGK Germany  1
HSコード  29419000
絵表示(GHS)
注意喚起語
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H315 皮膚刺激 皮膚腐食性/刺激性 2 警告 P264, P280, P302+P352, P321,P332+P313, P362
H317 アレルギー性皮膚反応を起こすおそれ 感作性、皮膚 1 警告 P261, P272, P280, P302+P352,P333+P313, P321, P363, P501
H319 強い眼刺激 眼に対する重篤な損傷性/眼刺激 性 2A 警告 P264, P280, P305+P351+P338,P337+P313P
H334 吸入するとアレルギー、喘息または、呼吸困難 を起こすおそれ 感作性、呼吸器 1 危険 P261, P285, P304+P341, P342+P311,P501
H335 呼吸器への刺激のおそれ 特定標的臓器毒性、単回暴露; 気道刺激性 3 警告
注意書き
P261 粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。
P284 呼吸用保護具を着用すること。
P305+P351+P338 眼に入った場合:水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。
P405 施錠して保管すること。

セフタジジム 価格 もっと(10)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01TRCC244100 セフタジジム五水和物(Contain 1 equivalent of Na2CO3 as stabilizer)
Ceftazidime Pentahydrate(Contain 1 equivalent of Na2CO3 as stabilizer)
78439-06-2 25mg ¥12500 2018-12-26 購入
富士フイルム和光純薬株式会社(wako) W01TRCC244100 セフタジジム五水和物(Contain 1 equivalent of Na2CO3 as stabilizer)
Ceftazidime Pentahydrate(Contain 1 equivalent of Na2CO3 as stabilizer)
78439-06-2 250mg ¥13800 2018-12-26 購入
Sigma-Aldrich Japan C0690500 European Pharmacopoeia (EP) Reference Standard
Ceftazidime European Pharmacopoeia (EP) Reference Standard
78439-06-2 c0690500 ¥33600 2018-12-25 購入
Sigma-Aldrich Japan 1098130 United States Pharmacopeia (USP) Reference Standard
Ceftazidime pentahydrate United States Pharmacopeia (USP) Reference Standard
78439-06-2 300mg ¥71100 2018-12-25 購入
富士フイルム和光純薬株式会社(wako) W01USP1098130 セフタジジム五水和物
Ceftazidime Pentahydrate
78439-06-2 300mg ¥73500 2018-12-26 購入

セフタジジム 化学特性,用途語,生産方法

効能

抗生物質, 細胞壁合成阻害薬

商品名

モダシン (グラクソ・スミスクライン)

説明

Ceftazidime is the latest third generation cephalosporin to reach the market. It has one of the broadest spectrums of the cephalosporins, similar in many regards to that of cefotaxime. It is particularly active against Pseudomonas aeruginosa, being perhaps 4-5 times more potent in vitro than moxalactam and cefotaxime.

化学的特性

White Solid

Originator

Glaxo (United Kingdom)

使用

Third generation cephalosporin antibiotic. Antibacterial.

定義

ChEBI: A hydrate that is the pentahydrate of ceftazidime, a cephalosporin having 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino and 3-pyridinium-1-ylmethyl side-groups.

brand name

Fortaz (GlaxoSmithKline); Tazicef (Hospira); Tazidime (Lilly);FORTAM.

抗菌性

Its activity is comparable to that of cefotaxime and ceftizoxime, but it is more active against Ps. aeruginosa, including almost all gentamicin-resistant strains, and Burk. cepacia. It is, however, less active against Staph. aureus. It is stable to a wide range of β-lactamases, but is hydrolyzed by some TEM variants.

薬物動態学

Cmax 500 mg intramuscular: 18–20 mg/L
2 g intravenous (20-min infusion): 185 mg/L end infusion
Plasma half-life: 1.5–2 h
Volume of distribution: 16 L
Plasma protein binding: c. 10%
No accumulation was seen in subjects receiving 2 g every 12 h over 8 days. In premature infants given 25 mg/kg every 12 h, mean peak plasma concentrations were 77 mg/L after intravenous and 56 mg/L after intramuscular administration, with plasma elimination half-lives of 7.3 and 14.2 h, respectively. Postnatal age was the most important determinant of elimination rate, which was halved after 5 days. In newborn infants given 50 mg/kg intravenously over 20 min, mean peak plasma concentrations varied inversely with gestational age from 102 to 124 mg/L, with half-lives of 2.9–6.7 h.
Distribution
The concentration into serous fluids reaches 50% or more of the simultaneous serum level. In patients given 1 g intravenously during abdominal surgery, detectable concentrations appeared within a few minutes in the peritoneal fluid, reaching a peak around 67 mg/L with a half-life of 0.9 h. Following a similar intravenous dose, a mean peak of 9.4 mg/L was reached at 2 h in ascitic fluid. Concentrations in middle ear fluid after 1 g intravenously were broadly comparable to those of the plasma.
In patients with meningitis, CSF concentrations of 2–30 mg/L have been found 2–3 h after doses of 2 g intravenously over 30 min given every 8 h for four doses. Concentrations are substantially less in the absence of meningitis. Concentrations of 3–27 mg/g were found in patients with intracranial abscesses treated with 0.5–2 g every 8 h. Concentrations around 0.4 mg/g in skin, 0.6 mg/g in muscle and 0.2 mg/g in fatty tissue have been found in patients given 2 g intravenously over 5 min preoperatively. A similar dose has produced mean prostate tissue:serum ratios of around 0.14. Effective concentrations are achieved in bone: in patients given 1 g intravenously mean bone concentrations were 14.4 mg/kg 35–40 min after the dose. There is secretion in breast milk, peak concentrations being around 5 mg/L at about 1 h in patients receiving 2 g intravenously every 8 h.
Metabolism and excretion
No metabolites have been detected. Elimination is almost exclusively renal, predominantly via the glomerular filtrate, with 80–90% of the dose appearing in the urine in the first 24 h. Elimination half-life is inversely correlated with creatinine clearance: as the values fall to 2–12 mL/min, the mean plasma half-life rises to 16 h. In patients maintained on hemodialysis the half-life fell to 2.8 h on dialysis. No accumulation occurred over 10 days in severe renal impairment on a daily dose of 0.5–1 g.
Concentrations of 6.6–58 mg/L have been found in bile 25–160 min after the dose at times when the mean serum concentration was 77.4 mg/L. In T-tube bile there was considerable interpatient variation, with mean concentrations of 34 mg/L at 1–2 h after the dose. No accumulation occurs in patients with impaired hepatic function, but the presence of ascites, low plasma albumin and accumulation of proteinbinding inhibitors may increase the volume of distribution.

臨床応用

It is used, often combined with an aminoglycoside, to treat a wide range of severe urinary, respiratory and wound infections, mostly due to enterobacteria or Ps. aeruginosa. Reference is made to its use in pneumonia, septicemia, meningitis (especially if caused by Ps. aeruginosa), peritonitis, osteomyelitis, neonatal sepsis, burns and melioidosis. Concern has been expressed at the relative frequency with which failure is associated with superinfection or the emergence of resistance.

副作用

It is generally well tolerated. Preparations containing arginine have replaced those with sodium carbonate, which causes pain on intramuscular injection. Reactions common to cephalosporins have been observed in some patients, including positive antiglobulin tests without hemolysis, raised liver function test values, eosinophilia, rashes, leukopenia, thrombocytopenia and diarrhea, occasionally associated with toxigenic C. difficile.
Failure of therapy has been associated with superinfection with resistant organisms, including Staph. aureus, enterococci and Candida. Resistance caused by induction of chromosomal β-lactamases may emerge in Ps. aeruginosa, Ser. marcescens or Enterobacter spp.

セフタジジム 上流と下流の製品情報

原材料

準備製品


セフタジジム 生産企業

Global( 93)Suppliers
名前 電話番号 ファックス番号 電子メール 国籍 製品カタログ 優位度
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3203 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20680 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32457 55
Hangzhou FandaChem Co.,Ltd.
0086 158 5814 5714 (Mobile; WhatsApp; Telegram)
+86-571-56059825 fandachem@gmail.com CHINA 2562 55
PI & PI BIOTECH INC.
020-81716320
020-81716319 Sales@pipitech.com CHINA 2543 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070;product@chemlin.com.cn
product@chemlin.com.cn CHINA 3015 60
Xiamen AmoyChem Co., Ltd
+86 (0)592-605 1114
sales@amoychem.com CHINA 6374 58
Hubei Jusheng Technology Co.,Ltd.
86-188-71490254
peter@hubeijusheng.com CHINA 20095 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 20516 58
Shanghai Boyle Chemical Co., Ltd.
86-21-57758967 sales@boylechem.com China 2927 55

78439-06-2(セフタジジム)キーワード:


  • 78439-06-2
  • sn401pentahydrate
  • CEFTAZIME
  • Kefazim
  • (6R,7R)-7-[[(2Z)-2-(2-Amino-1,3-thiazol-4-yl)-2-(1-hydroxy-2-methyl-1-oxopropan-2-yl)oxyiminoacetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
  • Ceftazidime
  • 1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]pyridinum
  • Ceftazidieme Pentahydrate
  • 1-[[(6r,7r)-7-[[(2z)-(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino] acetyl] amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0] oct-2-en-3-yl]methyl]pyridinum hydroxide inner salt
  • 1-[[(6R,7R)-7-[[(2Z)-(2-AMINO-4-THIAZOLYL)[(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL]AMINO]-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO[4.2.0]OCT-2-EN-3-YL]METHYL]PYRIDINUM PENTAHYDRATE
  • Ceftazidime Pentahydrate (300 mg)
  • PyridiniuM,1-[[(6R,7R)-7-[[(2Z)-(2-aMino-4-thiazolyl)[(1-carboxy-1-Methylethoxy)iMino]acetyl]aMino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]Methyl]-,inner salt, hydrate (1:5)
  • 1-[[(6R,7R)-7-[[(2Z)-2-(2-AMino-4-thiazolyl)-2-[(1-carboxy-1-Methylethoxy)iMino]acetyl]aMino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]Methyl]pyridiniuM Inner Salt Pentahydrate
  • CeftazidiMe Pentahydrate (Contain 1 equivalent of Na2CO3 as stabilizer)
  • Ceftazidime Pentahydrate, >=99%
  • Ceftazidime
  • CEFTAZIDIME PENTAHYDRATE
  • cazpentahydrate
  • gr20263pentahydrate
  • innersalt,(6r-(6-alpha,7-beta(z)))-droxidpentahydrate
  • セフタジジム五水和物(CONTAIN 1 EQUIVALENT OF NA2CO3 AS STABILIZER)
  • セフタジジム五水和物
  • セフタジジム
  • セフタジジム水和物
  • セフタジジム水和物 (JP17)
Copyright 2017 © ChemicalBook. All rights reserved